EP Patent

EP3725305A1 — Pharmaceutical composition containing baricitinib hydrobromide

Assigned to Zentiva KS · Expires 2020-10-21 · 6y expired

What this patent protects

The invention relates to a composition for a pharmaceutical solid drug form, which comprises baricitinib hydrobromide in the amount of 2.5 % w/w or more, relative to the total weight of the composition, a filler, and at least one additional pharmaceutically acceptable excipient. …

USPTO Abstract

The invention relates to a composition for a pharmaceutical solid drug form, which comprises baricitinib hydrobromide in the amount of 2.5 % w/w or more, relative to the total weight of the composition, a filler, and at least one additional pharmaceutically acceptable excipient. Such composition has a number of technological advantages.The additional pharmaceutically acceptable excipients may include disintegrants and lubricants.

Drugs covered by this patent

Patent Metadata

Patent number
EP3725305A1
Jurisdiction
EP
Classification
—
Expires
2020-10-21
Drug substance claim
No
Drug product claim
No
Assignee
Zentiva KS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.